Abstract

You have accessJournal of UrologyKidney Cancer: Epidemiology & Evaluation/Staging I1 Apr 2017MP22-02 SYNERGISTIC PROGNOSTIC IMPACT OF ELEVATED DE RITIS RATIO AND RENAL SCORE FOR PREDICTION OF SURVIVAL OUTCOMES IN RENAL CELL CARCINOMA AFTER SURGICAL TREATMENT Aaron Bloch, Zachary Hamilton, Charles Field, Katherine Fero, Sean Berquist, Abd-elrahma Hassan, Brittney Cotta, Daniel Han, Richmond Owusu, Sunil Patel, Fang Wan, James Proudfoot, and Ithaar Derweesh Aaron BlochAaron Bloch More articles by this author , Zachary HamiltonZachary Hamilton More articles by this author , Charles FieldCharles Field More articles by this author , Katherine FeroKatherine Fero More articles by this author , Sean BerquistSean Berquist More articles by this author , Abd-elrahma HassanAbd-elrahma Hassan More articles by this author , Brittney CottaBrittney Cotta More articles by this author , Daniel HanDaniel Han More articles by this author , Richmond OwusuRichmond Owusu More articles by this author , Sunil PatelSunil Patel More articles by this author , Fang WanFang Wan More articles by this author , James ProudfootJames Proudfoot More articles by this author , and Ithaar DerweeshIthaar Derweesh More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.656AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Renal Cell Carcinoma (RCC) is a metabolically driven neoplasm. Inflammatory markers and morphometric measures have been suggested to be predictive for prognosis. We investigated the impact of a novel combination of preoperative tumor morphology (RENAL score) and a laboratory based inflammatory marker (DeRitis Ratio, AST/ALT) on survival outcomes in localized RCC. METHODS Single center, retrospective analysis of 524 patients with RCC (312 PN, 212 RN, mean follow up 35.8 months) from 2003-2015. A priori, we assigned a positive marker score of 1 if RENAL >8 or DeRitis >1.5. Patients were stratified by increasing positive markers (0=RENAL ≤8 and DeRitis ≤1.5, 1=RENAL >8 or DeRitis >1.5, 2=RENAL >8 and DeRitis>1.5). Primary outcome was overall survival (OS). Cox models and Kaplan-Meier curves were utilized. RESULTS 524 patients, 68% male, mean age 64.8 ± 12.6 years, mean BMI 29.1 ± 6.5, mean DeRitis 1.1 ± 0.4. With regards to tumor characteristics, mean clinical tumor size was 4.8 ± 3.3cm and median RENAL score was 8 (IQR 6-10). For clinical staging, 74% were cT1, 19% cT2, and 6% were >T2. On Cox model for OS, RENAL >8 (HR 1.95, p=0.003) and DeRitis >1.5 (HR 3.74, p<0.001) were significantly associated with worsened survival. On Cox model output for OS and marker score, we found 1 marker (HR 1.83, p=0.011) and 2 markers (HR 7.68, p<0.001) were significantly associated with worsened survival (figure). CONCLUSIONS Novel combination of a morphological score (RENAL) and an inflammatory marker (DeRitis ratio) was associated with worsened OS in RCC after surgical treatment. Our findings point towards development and validation of a prognostic index to assist in risk stratification and follow up protocols for RCC. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e256-e257 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Aaron Bloch More articles by this author Zachary Hamilton More articles by this author Charles Field More articles by this author Katherine Fero More articles by this author Sean Berquist More articles by this author Abd-elrahma Hassan More articles by this author Brittney Cotta More articles by this author Daniel Han More articles by this author Richmond Owusu More articles by this author Sunil Patel More articles by this author Fang Wan More articles by this author James Proudfoot More articles by this author Ithaar Derweesh More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call